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 Background The mitogen-activated protein–kinase pathway consisting of the kinases RAF, MEK, and ERK is central to cell pro-
liferation and survival and is deregulated in more than 90% of melanomas. MEK inhibitors are currently trialled 
in the clinic, but despite efficient target inhibition, cytostatic rather than cytotoxic activity limits their efficacy.
 Methods We assessed the cytotoxicity to MEK inhibitors (PD184352 and selumetinib) in melanoma cells by toluidine-blue 
staining, caspase 3 cleavage, and melanoma-sphere growth. Western blotting and quantitative real-time poly-
merase chain reaction were applied to determine SMAD-specific E3 ubiquitin protein ligase 2 (SMURF2), PAX3, 
and MITF expression. Human melanoma samples (n = 77) from various stages were analyzed for SMURF2 and 
PAX3 expression. RNA interference was performed to target SMURF2 during MEK inhibition in vivo in melanoma 
xenografts in mice and zebrafish. All statistical tests were two-sided.
 Results Activation of transforming growth factor β (TGF-β) signalling sensitized melanoma cells to the cytotoxic effects 
of MEK inhibition. Melanoma cells resistant to the cytotoxic effects of MEK inhibitors counteracted TGF-β sig-
nalling through overexpression of the E3 ubiquitin ligase SMURF2, which resulted in increased expression of 
the transcription factors PAX3 and MITF. High MITF expression protected melanoma cells against MEK inhibitor 
cytotoxicity. Depleting SMURF2 reduced MITF expression and substantially lowered the threshold for MEK inhibi-
tor–induced apoptosis. Moreover, SMURF2 depletion sensitized melanoma cells to the cytotoxic effects of selu-
metinib, leading to cell death at concentrations approximately 100-fold lower than the concentration required to 
induce cell death in SMURF2-expressing cells. Mice treated with selumetinib alone at a dosage of 10 mg/kg body 
weight once daily produced no response, but in combination with SMURF2 depletion, selumetinib suppressed 
tumor growth by 97.9% (95% confidence interval = 38.65% to 155.50%, P = .005).
 Conclusions Targeting SMURF2 may be a novel therapeutic approach for increasing the antitumor efficacy of MEK inhibitors.
  J Natl Cancer Inst 2013;105:33–46
The mitogen-activated protein (MAP)–kinase pathway, consist-
ing of the kinases RAF, MEK, and ERK, is hyperactivated in more 
than 90% of melanomas, and this is mainly triggered by a mutated 
BRAF-kinase, which constitutively activates MEK (1,2). Currently, 
inhibitors of MEK are being evaluated in the clinic, but although 
they show some single-agent activity, the overall responses are 
much lower than expected (3,4). Importantly, the doses of MEK 
inhibitor used in reported trials effectively produce target inhibi-
tion and suppress proliferation (4,5). These observations suggest 
that cytostatic effects may not be sufficient to produce a major 
response in patients and that the majority of tumors are intrinsi-
cally refractory to cytotoxic effects of MEK inhibition.
Indeed, from studies in melanoma cell lines, it is clear that 
cytotoxic effects of MEK inhibitors in melanoma cells generally 
occur either at concentrations considerably higher than the 
concentrations needed to produce an antimitotic effect or after 
continuous long-term exposure to the drug (6–8). However, dose-
limiting toxicity or a short half-life of the inhibitor prevents these 
conditions being satisfied in vivo (3,5). Moreover, frequently 
BRAF-mutant cells display high resistance to MEK inhibitor–
induced apoptosis despite efficient target inhibition (9,10), which 
points to the activation of additional pathways in these cells that 
enable them to survive even at very low levels of ERK activation. 
Thus, in addition to recently discovered mechanisms reinstating 
MAP-kinase pathway activation in the presence of inhibitor (11–
14), abrogation of the cytotoxic effects of MEK inhibitors brought 
about by parallel pathways must be considered as a possible 
resistance mechanism. Phosphatidylinositol-3-kinase or its 
upstream regulators activate such a pathway (10,15,16), and trials 
using phosphatidylinositol-3-kinase pathway inhibitors combined 
with MEK inhibitors are currently underway. However, like the 
MAP-kinase pathway, phosphatidylinositol-3-kinase signalling is 
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central to all nontumor cells, and the toxicity of these inhibitors is 
a limiting factor (17,18).
We, therefore, aimed to identify melanoma specific proteins 
that counteract MEK inhibitor–induced cytotoxic effects. Such 
proteins may be useful predictive markers for the sensitivity of mel-
anoma cells to MEK inhibitors. Moreover, targeting such proteins 
may 1) improve the initial response to MEK inhibitors by enhanc-
ing their cytotoxic effects, thus overcoming primary resistance, and 
2)  prevent secondary acquired resistance that develops from the 
selection for primary resistant cells during drug treatment.
Materials and Methods
Cell Culture, Reagents, and Transfections
Human melanoma cell lines, derived from patients with either pri-
mary (888mel) or metastatic (A375, WM266-4, SK-Mel2, 501mel, 
and WM164) melanoma lesions, were grown in Dulbecco’s modi-
fied Eagle medium containing 10% fetal calf serum (PAA, Yeovil, 
UK). A375, WM266-4, WM164, and SK-Mel2 cells were from 
American Type Culture Collection (LGC, Middlesex, UK), 501mel 
and 888mel were a gift from Steven Rosenberg (National Cancer 
Institute, Bethesda, MD). All cell lines are positive for the mela-
noma marker MITF: SK-Mel2 cells harbor an NRAS mutation, and 
the other melanoma cell lines were confirmed to harbor a BRAF 
mutation. Human dermal fibroblasts were a gift from Guillaume 
Jacquement (University of Manchester, Manchester, UK) and 
grown in Dulbecco’s modified Eagle medium containing 10% 
fetal calf serum. Normal human melanocytes (Cascade Biologics, 
Invitrogen, Carlsbad, CA) were cultured in medium 154 with human 
melanocyte growth supplement 2 (Cascade Biologics). PD184352 
was from Axon Medchem (Groningen, The Netherlands), and 
selumetinib (AZD6244) was from Selleck Chemicals (Newmarket, 
UK). Transforming growth factor β (TGF-β) was from Sigma 
(St Louis, MO). Cells were transfected with plasmid DNA using 
Attractene transfection reagent (Qiagen, Valencia, CA) and with 
small interfering RNAs (siRNAs) using INTERFERin siRNA-
transfection reagent (Polyplus, Illkirch, France) according to the 
manufacturer’s instructions. For the generation of A375 cells stably 
transfected with either the control vector pLKO or with differ-
ent SMAD-specific E3 ubiquitin protein ligase 2 (SMURF2)–spe-
cific small hairpin RNAs (shRNAs), cells were transfected with the 
respective circular plasmids (set of 5 shRNAs, #RHS4533; Open 
Biosystems, Huntsville, AL) and selected for puromycin (1µg/
ml) resistance. Clones S2-C4 and S2-C14 were isolated from cell 
populations transfected with different shRNA sequences. For the 
MEK inhibitor resistance colony formation assay, A375, WM266-
4, and SK-Mel28 cells were transfected with circular pEF-MITF 
or empty vector plasmids. Cells were plated in 10-cm dishes and 
incubated with 1µM PD184352 for 3 weeks before being formalin 
fixed, stained with crystal violet, and photographed. Quantification 
was achieved by spectrophotometrical analysis measuring the opti-
cal density at 555 nm (OD 555) of the solubilized dye.
Immunoblotting
Melanoma cells (3 × 105) were lysed in 150-µL sodium dodecyl sul-
fate sample buffer (62.5 mM Tris-hydrochloride [pH 6.8 at 25°C], 
2% weight/volume sodium dodecyl sulfate, 10% glycerol, 50 mM 
dithiothreitol, 0.01% weight/volume bromophenol blue) or lysis 
buffer [50 mm 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 
pH 7.5, 150 mM sodium chloride, 1.5 mM magnesium chloride, 
1 mM ethylene glycol tetraacetic acid, 10% glycerol, 1% Triton 
X-100, 1 mM phenylmethanesulfonyl fluoride, 0.2 mM sodium 
orthovanadate, 10 mg/mL leupeptin, 10 mg/ml aprotinin) for 20 
minutes at 4ºC and analyzed by standard immunoblotting pro-
tocols. The same amount of protein was loaded in each lane, and 
primary antibodies were detected by luminescence using peroxi-
dase-coupled secondary antibodies (Jackson, Stratech, Newmarket, 
UK). The primary antibodies used were: phospho-ERK (mouse 
monoclonal MAPK-YT, 1:10,000 dilution; Sigma); ERK2 (rabbit 
polyclonal C-14, 1:10,000 dilution), PAX3 (goat-polyclonal N-19, 
1:1000 dilution), and SMURF2 (rabbit polyclonal H-50, 1:1000 
dilution) from Santa Cruz Biotechnolgy (Santa Cruz, CA); MITF 
(mouse monoclonal, C5, 1:500 dilution; Neomarkers, Lab Vision, 
Runcorn, UK); PARP (mouse monoclonal C2-10, #556362, 1:3000 
dilution; BD Biosciences, Oxford, UK); and cleaved caspase 3, 
SMAD2, and phospho-SMAD2, SMAD3, and SMAD4 (all rabbit 
polyclonal, 1:1000 dilution) from Cell Signaling (Boston, MA).
Detection of Cell Death
The cellular sub-G1 fraction was determined by fluorescence-
activated cell sorting using propidium iodide staining and stand-
ard protocols. Quantification of live cells was performed by crystal 
violet or toluidine blue staining of formalin-fixed cells, and subse-
quent spectrophotometrical analysis was performed by measuring 
the OD 555 of the solubilized dye.
RNA Isolation and Quantitative Real-Time Polymerase 
Chain Reaction (qPCR) Analysis
RNA was isolated with TRIZOL reagent (Invitrogen), and 
selected genes were amplified by qPCR using SYBR green 
(Qiagen) incorporation during the amplification reaction. Primer 
sequences (forward; reverse) were as follows: PAX3 (AGGAT-
GCGGCTGATGGAACTCACTG; CCAGGATGATGCGGC-
CGGGCCC GGG); MITF (CCGTCTCTCACTGGATTGGT; 
TACTTGGTGGGGTTTTCGAG); SMURF2 (GCAACAA-
GGCCAGGTGTATT; ACCACTTGCTGTTGCTGTTG); 
GAPDH (CAATGACCCC TTCATTGACC; GACAAGCTTC-
CCGTTCTCAG); and β-actin (GCAAGCAGGAGT ATGAC-
GAG; CAAATAAAGCCATGCCAATC).
siRNAs and shRNAs
All siRNAs were from Thermo Scientific Dharmacon 
(Loughborough, UK). The sequences of the individual siRNAs 
were as follows: SMURF2#1 (GAUGAGAACACUCCAAUUA), 
SMURF2#2 (GACCAUACCUUCUGUGUUG), SMURF2#3 
(CAAAGUGGAAUCAGCAUUA), SMURF2#4 (GAACAAC 
ACAAUUUACAGA), MITF#1 (GAACGAAGAAGAAGAUUU 
AUU), MITF#2 (AAAGCAGUACCUUUCUACCAC), MITF#3 
(GACCUAACCUGUACAACAAUU), PAX3#1 (GAAACACCG 
UGCCGUCAGUUU), PAX3#2 (GAGACUGGCUCCAUAC 
GUCUU) and scrambled (nontargeting) control sequence (AAUAUAA 
UCACUAUCAGGUGC); S2-p was a ready-to-use SMURF2 
SMARTpool. The circular plasmids containing SMURF2-specific 
shRNAs were from Open Biosystems (Thermo Fisher, Loughborough, 
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UK). S2-sh#1 corresponds to clone TRCN0000003475, and S2-sh#2 
corresponds to clone TRCN0000003477.
Melanoma Three-Dimensional Spheroid Growth
A375 melanoma cells and the corresponding SMURF2 shRNA 
derivatives stably expressing green fluorescent protein were resus-
pended in Dulbecco’s modified Eagle medium containing 5% 
fetal calf serum and 1.5% methylcellulose (Sigma). The cell sus-
pension was transferred into a 96-well plate (1000 cells per well), 
and spheres were allowed to form over a period of 48 to 72 hours. 
Spheres were then transferred into 0.5-mL fibrillar bovine dermal 
collagen (2.3 mg/mL; Nucaton, Leimuiden, The Netherlands) 
with one sphere per well of a 24-well plate. Once the collagen was 
set, Dulbecco’s modified Eagle medium containing 10% fetal calf 
serum was added, and after approximately 16 hours, drugs were 
added to the medium at indicated concentrations. Dead cells were 
identified by staining of nonfixed cells with ethidium bromide 
(100 µg/mL; Sigma) for 10 minutes, followed by three washes with 
phosphate-buffered saline. Green fluorescent protein–express-
ing spheres were monitored, and ethidium bromide intensity was 
assessed using a Leica DM IL HC inverted microscope and a 
FC340 Cooled Monocrome camera (Leica Microsysytems).
Melanoma cDNA Tissue Array
Two melanoma TissueScan cDNA arrays, MERT101 and 
MERT102 (Origene, Rockville, MD), were analyzed for the 
expression of SMURF2 and PAX3. The arrays consisted of cDNA 
derived from stage III (n = 36) and stage IV (n = 41) melanomas, 
staged according to the revised TNM classification with mini-
mum stage grouping (19), and from normal skin (n  =  6), which 
was supplemented with additional cDNA derived from human 
fibroblasts, keratinocytesm, and melanocytes. The expression in 
melanocytes was set to one. The cDNA samples were preampli-
fied using the TaqMan PreAmp Master Mix Kit (PN4384267, 
Applied Biosystems, Carlsbad, CA) according to the manufacturer’s 
instructions. qPCR was carried out with TaqMan Gene Expression 
Master Mix (PN4369016, Applied Biosystems). β-Actin expression 
was used to normalize relative SMURF2 and PAX3 expression. 
Experiments were performed as multiplex PCR reactions using 
TaqMan probes (Applied Biosystems) for SMURF2 (Hs00224203, 
FAM labelled) or PAX3 (Hs00240950, FAM labelled) with a differ-
entially labelled β-actin probe (Hs99999903, VIC labelled).
Melanoma Xenografts
All procedures involving animals were approved by the Animal 
Ethics Committees of the Institute of Cancer Research in accord-
ance with National Home Office regulations under the Animals 
(Scientific Procedures) Act 1986 and according to the guidelines 
of the Committee of the National Cancer Research Institute (20).
Xenografts in Zebrafish. Zebrafish (Danio rerio) were raised 
and maintained at the University of Manchester Biological 
Services Unit. Zebrafish xenografts were generated by injection 
of approximately 1000 melanoma cells into the pericardiac space 
surrounding the heart of embryos that were 48 hours postfertiliza-
tion. Subsequently, groups of six larvae per condition, randomly 
assigned were treated with either 20 nM or 100 nM PD184352 or 
the vehicle dimethyl sulfoxide (DMSO). The drug was added to the 
fish medium, and larvae were grown at 34°C ambient temperature 
in chorion water. Before drug addition (day 1) and 3 days after drug 
addition, anesthetized larvae (MS222, Sigma) were imaged using a 
Leica SP5 confocal microscope (Leica Microsystems). Images were 
processed using Volocity software (Perkin Elmer, Cambridge, UK.)
Xenografts in Mice.  For xenografts, 4 × 106 A375pLKO or A375 
S2-C14 cells in 0.1 mL phosphate-buffered saline were inoculated 
subcutaneously into one flank each of female CD1 nude mice 
(Charles River, Margate, Kent, UK). When mice had developed 
melanoma nodules of approximately 100 mm3, mice were randomly 
assigned to five per group, and drug administration was initiated (day 
0). Treatment was by oral gavage once daily with vehicle (5% DMSO, 
95% water), or 3 mg or 10 mg/kg body weight selumetinib in vehicle. 
Tumor size was determined at days 7, 12, 19, 26, and 29 by calliper 
measurements of tumor length, width, and depth, and volume was 
calculated as volume = 0.5236 × length × width × depth (mm).
Statistical Analysis
All experiments were performed a minimum of three times. Data 
represent the results for assays performed in triplicate or more, and 
error bars represent 95% confidence intervals (CIs). All statistics 
were based on continuous variables. Comparisons between more 
than two treatment groups were made using predominately one-
way analysis of variance with Tukeys’s, Dunnett’s or Bonferroni’s 
post hoc test for multiple comparisons. For comparisons between 
two groups, the Student’s t test was applied. Drug dose–response 
curves were analyzed with a nonlinear regression curve fit model. 
A ranking linear regression fit with Wald–Wolfowitz runs test was 
used to compare SMURF2 and PAX3 expression from cDNA 
array data. P values of less than.05 were considered statistically 
significant. All statistical tests were two-sided. All statistical analysis 
and calculations were performed using GraphPad Prism version 
4.00 for Mac OS (GraphPad Software Inc, San Diego, CA).
results
MITF Expression and Resistance to MEK Inhibitor–
Induced Apoptosis in Melanoma Cells
To identify melanoma specific proteins allowing survival in the 
presence of MEK inhibitor, we exposed BRAF-mutant A375 mela-
noma cells to cytotoxic concentrations of PD184352 for 4 days and 
isolated individual clones that were able to grow in the presence 
of drug (Figure 1, A). Immunoblot analysis of individual clones for 
expression of the central regulator of melanoma cell fate, MITF 
(21–24), identified increased expression compared with the parental 
cell line A375 (Figure 1, B). Further analysis confirmed that in con-
trast with parental A375 cells, A375-R1 and A375-R4 cells were able 
to survive in the presence of MEK inhibitor, which was indicated 
by the absence of an increased subG1 fraction after MEK inhibi-
tor exposure (Figure 1, C). However, the two resistant clones still 
responded to the MEK inhibitor with reduced ERK phosphoryla-
tion (Figure 1, D) and reduced progression into S-phase when com-
pared with the parental cells (cells in S-phase: R1: 25.6% vs 7.12%, 
difference = 18.48%, 95% CI = 13.53 to 23.42, P = .002; R4: 27.87% 
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vs 7.7%, difference 20.17%, 95% CI = 14.93 to 25.40, P  <  .001) 
(Figure 1, E). As a consequence, when cultured in the presence of 
drug, the resistant cells displayed slow but continuous growth, as 
was seen in a long-term growth experiment. When, after 12 days 
of treatment, the number of cells in a culture dish was assessed by 
staining with crystal violet, the staining intensity of plates contain-
ing A375-R1 or A375-R4 cells was considerably higher than in 
plates containing A375 cells. The difference in cell number was also 
visible when cells were photographed (Figure 1, F).
MITF depletion from the resistant A375-R1 and A375-R4 cells by 
RNA interference (RNAi) sensitized the cells to PD184352-induced 
caspase 3 cleavage (Figure 2, A). Furthermore, ectopic overexpression 
of MITF in three different sensitive cell lines increased the number 
of colonies growing after 3 weeks in the presence of MEK inhibitor 
when compared with cell lines that had been transfected with 
an empty vector (OD 555 of stained cells: A375: 0.046 vs 0.300, 
difference = −0.25, 95% CI = −0.30 to −0.21, P < .001; SKMEL28: 
OD 555 = 0.105 vs 0.335, difference = −0.23, 95% CI = −0.28 to −0.18, 
P < .001; WM2664: OD 555 = 0.033 vs 0.155, difference = 0.12, 95% 
CI = −0.15 to −0.10, P < .001) (Figure 2, B). These initial findings 
indicated that MITF both is required and sufficient to produce 
resistance to MEK inhibitor–induced cell death.
Effect of SMURF2 on MITF Expression and MEK Inhibitor 
Resistance
To identify the mechanism leading to increased MITF expression in 
the acquired resistant A375-R1 and R4 cells, we analyzed the cells for 
the expression of the MITF upstream regulators BRN2 and MITF 
and detected increased expression of only PAX3 (Figure 3, A). PAX3 
is a positive transcriptional regulator of MITF (25) and its RNAi-
mediated depletion in A375 and WM266-4 melanoma cells resulted 
in reduced MITF levels (Supplementary Figure 1, A, available online).
Figure 1. MITF and resistance to MEK inhibitor–induced apoptosis. A) 
Schematic of the protocol used for the selection of MEK inhibitor resist-
ant clones. A375 melanoma cells were exposed to 1 µM PD184352 (PD) 
for 4 days, which resulted in greater than 98% cell death. Surviving cells 
were expanded at 0.5 µM PD184352 for an additional 3 weeks. Individual 
clones that had grown in the presence of 0.5 µM drug were isolated. 
B) Western blot of sensitive (S) parental A375 cells and MEK inhibitor–
resistant clones for MITF and ERK2 (loading control). C) Quantification 
of cells in the subG1 fraction of a fluorescence-activated cell sorting 
(FACS) analysis of parental A375 cells and MEK inhibitor–resistant clones 
treated with dimethyl sulfoxide (DMSO) (D) or 1µM PD184352 (PD) for 
72 hours. Bars represent means from three independent experiments; 
error bars refer to 95% confidence intervals; ***P < .001; NS = P > .05. 
A two-sided Student’s t test was used. D) Western blot for phosphoERK 
(pERK) and ERK2 (loading control) of parental A375 cells (A) and MEK 
inhibitor resistant clones (R1, R4) treated with either DMSO or the indi-
cated concentrations of PD184352 (PD). E) Quantification of cells in the 
S-phase fraction of a FACS analysis of parental A375 cells and MEK 
inhibitor–resistant clones treated with DMSO (D) or 1µM PD184352 (PD) 
for 72 hours. Bars represent means from three independent experi-
ments; error bars refer to 95% confidence intervals; ***P < .001. A two-
sided Student’s t test was used. F) Parental A375 and resistant clones 
R1 and R4 were cultured in the absence (DMSO) or presence of 0.5 µM 
PD184352 for 12 days. Cells were fixed, photographed, and stained with 
crystal violet. The intensity of staining reflects the number of cells that 
had grown under the various conditions. Individual photographs of 
cells grown in the presence of PD148352 are shown. Scale bar = 50 µm.
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PAX3 and MITF regulation have been placed downstream of 
TGF-β in melanocytes, where a SMAD4/SMAD2-containing 
complex directly suppresses PAX3 expression (26). We found this 
described mechanism was conserved in melanoma cells, where 
treatment of the melanoma cells with TGF-β suppressed PAX3 
and MITF RNA expression when compared with nontreated mela-
noma cells (normal human melanocytes: relative PAX3 expression in 
untreated cells = 1 vs 0.43, in TGF-β-treated cells, difference = 0.57, 
95% CI  =  0.21 to 0.92, P < .001; relative MITF expression in 
untreated cells = 1 vs 0.17, in TGF-β-treated cells, difference = 0.83, 
95% CI = 0.48 to 1.19, P < .001; A375: relative PAX3 expression in 
untreated cells = 1 vs 0.28 in TGF-β-treated cells, difference = 0.72, 
95% CI  =  0.36 to 1.07, P < .001; relative MITF expression in 
untreated cells = 1 vs 0.64 in TGF-β-treated cells, difference = 0.36, 
95% CI = 0.05 to 0.72, P = 0.02) (Figure 3, B). Treatment of A375-R1 
and R4 cells with TGF-β and PD184352 induced caspase 3 cleav-
age (Figure 3, C). Moreover, the treatment of melanoma cells with 
TGF-β and PD184352 reduced cell survival in the acquired resistant 
melanoma cells, with approximately 80% reduction in cell numbers 
(R1: 78.5%, 95% CI = 75.74% to 83.16%, P < .001; R4: 81.5%, 95% 
CI = 79.75% to 83.07%, P < .001) (Figure 3, D).
Because activating TGF-β signalling suppressed MITF 
expression and sensitized melanoma cells to MEK inhibitor–induced 
cell death, we hypothesized that counteracting TGF-β signalling 
could provide a mechanism for MITF-mediated MEK inhibitor 
resistance. Indeed, we detected statistically significantly (R1: P 
< .001; R4: P < .001) increased RNA expression of SMURF2 
(Figure 3, E), an E3 ubiquitin ligase that regulates the degradation 
and activity of SMAD proteins (27,28) in the MEK inhibitor–
resistant cell lines compared with the parental A375 cells. We found 
that SMURF2 suppresses the amount of SMAD2 in melanoma cells 
(Figure 3, E; Supplementary Figure 2, A, available online), and that 
high SMURF2 levels paralleled high PAX3 expression in A375-R1 
and A375-R4 cells (Figure  3, F). This high PAX3 expression is 
dependent on SMURF2 because SMURF2 depletion using four 
individual siRNAs completely abolished increased PAX3 expression 
(Figure  3, F). Accordingly, MITF expression was also severely 
reduced (Supplementary Figure 2, C and D, available online).
Depletion of SMURF2 from A375-R1 or A375-R4 cells did 
not impact their viability, but additional treatment with PD184352 
induced cell death (Supplementary Figure, 2, B and E, available 
online). A  dose–response analysis showed that SMURF2 deple-
tion via RNAi overcomes MEK inhibitor resistance, and the GI50 
(concentration of MEK inhibitor required to reduce the cell num-
ber by 50% compared with DMSO control) for PD184352 in 
A375-R1 and A375-R4 cells was reduced 3- to 10-fold compared 
Figure 2. Effect of MITF on MEK inhibitor resistance. A) Western blot 
for MITF, cleaved caspase 3, and pERK of the resistant clones A375-R1 
and A375-R4 treated with a scrambled control or MITF-specific small 
interfering RNAs (siRNAs) (MI #1, MI #2, MI #3) for 48 hours, followed 
by 24-hour exposure to 1  µM PD184352 (PD) or dimethyl sufloxide 
(DMSO [D]). β-Actin was used as loading control. B) A375, SK-Mel28, 
and WM266-4 cells were transfected with an MITF expression vector 
or an empty vector (Vec). The Western blot (upper right panels) shows 
MITF expression 24 hours after the transfection. Note that the chosen 
short-film exposure does not detect endogenous MITF expression in 
WM266-4 and A375 cells. The cells were cultured for 3 weeks in the pres-
ence of PD184352, and resistant colonies were stained with crystal vio-
let. A representative stained cell image is shown to the left of the graph, 
which plots the mean number of crystal violet–positive cells from three 
independent assays; error bars refer to 95% confidence intervals; ***P 
< .001. A two-sided Student’s t test was used.
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Figure 3. Effects of transforming growth factor β (TGF-β) and SMURF2 
on melanoma cell sensitivity to MEK inhibition. A) Western blot of sen-
sitive (S) parental A375 cells and MEK inhibitor resistant clones R3, R6, 
R1, and R4 for MITF, PAX3, and ERK2 (loading control). B) Quantitative 
real-time polymerase chain reaction (PCR) analysis of PAX3 and MITF 
expression in normal human melanocytes (NHM) and A375 cells either 
unstimulated (–) or stimulated (transforming growth factor β [TGF-β]) 
for 24 hours with 5 ng/ml TGF-β. Bars represent means from three inde-
pendent experiments; error bars refer to 95% confidence intervals; 
***P < .001; *P = .02. A  two-sided Student’s t was used. C) Western 
blot of A375-R1 and A375-R4 cells for cleaved caspase 3, pERK,and 
ERK2 (loading control). The cells were either unstimulated (–) or stimu-
lated (TGF-β) for 24 hours with 5 ng/ml TGF-β in the presence of dime-
thyl sulfoxide (DMSO [D]) or 2 µM PD184352 (PD). D) Quantification of 
cell survival. A375-R1 and A375-R4 cells were treated with TGF-β for 48 
hours, followed by 24-hour exposure to 2 µM PD184352 (PD) or DMSO 
(D), before the cell number was assessed by toluidine staining. DMSO-
treated cells were set 100%. Bars represent means from three inde-
pendent experiments; error bars refer to 95% confidence intervals; 
***P < .001. Two-sided analysis of variance (ANOVA) with Bonferroni 
post hoc test was used. E) Quantitative real-time PCR and Western blot 
analysis of SMURF2 expression in parental A375 cells and the resistant 
clones R1 and R4. SMURF2 expression in A375 cells was set to 1. Bars 
represent means from three independent experiments; error bars refer 
to 95% confidence intervals; ***P < .001. A two-sided Student’s t test 
was used. F) Quantitative real-time PCR analysis of PAX3 expression 
in parental A375 cells and the resistant clones R1 and R4 transfected 
with either a scrambled control or four individual SMURF2-specific 
small interfering RNAs (siRNAs) (#1–#4). A375 cells treated with a 
scrambled control siRNA were set to 1.  Bars represent means from 
three independent experiments; error bars refer to 95% confidence 
intervals. ***P < .001. Two-sided ANOVA with Dunnett’s post hoc test 
was used. G) Dose–response curve of cell survival in the presence of 
PD184352. A375 cells and the resistant clones R1 and R4 were treated 
with a scrambled control or a SMURF2-specific siRNA (siS2#1) for 48 
hours, followed by the indicated concentrations of PD184352 for 24 
hours before they were fixed, stained with toluidine blue, and quanti-
fied measuring the optical density at 555 nm (OD 555) of solubilized 
dye. For each cell line, DMSO-treated cells were set to 100%, and 
percentage of cell survival at defined drug concentrations was deter-
mined. Drug dose–response curves were analyzed with a nonlinear 
regression curve fit model. H) A375-pLKO or small hairpin SMURF2-
expressing A375 cells (clone S2–C14; see Supplementary Figure  3, 
available online) were cultured for 3 weeks in the presence of 0.5 µM 
PD184352, and resistant colonies were stained with crystal violet, and 
the OD 555 was quantified. Values represent the results of five inde-
pendent experiments. ***P < .001. A  two-sided Student’s t test was 
used. Black circles represent cells stably transfected with the empty 
pLKO vector, black triangles represent cells stably transfected with a 
SMURF2–small hairpin RNA–expressing vector.
Downloaded from https://academic.oup.com/jnci/article-abstract/105/1/33/877707
by Library Institute of Cancer Research user
on 06 August 2018
JNCI | Articles 39jnci.oxfordjournals.org
with A375 cells (A375: 95% CI [GI50] = 1.47 to 2.66 µM; R1/siS2: 
95% CI [GI50] = 0.53 to 0.72 µM; R4/siS2: 95% CI [GI50] = 0.11 
to 0.18 µM) (Figure 3, G). Most important, stable expression of a 
SMURF2-specific shRNA in A375 cells (Supplementary Figure 3, 
available online) suppressed the development of acquired MEK 
inhibitor resistance, and the number of PD184352-resistant colo-
nies derived from small hairpin SMURF2 (shSMURF2) cells after 
3 weeks of drug exposure was severely reduced when compared 
with empty vector pLKO cells treated with MEK inhibitor (OD 
555 of stained cells, pLKO vs shSMURF: 0.3872 vs 0.1030, differ-
ence = 0.28, 95% CI = 0.21 to 0.36, P < .001) (Figure 3, H).
MITF Expression and Primary Resistance to MEK 
Inhibitor–Induced Cytotoxicity
We next extended our study to primary (innate) resistance to 
MEK inhibition in BRAF-mutant melanoma cells. High-MITF-
expressing cells (WM164, 888mel, 501mel), which are repre-
sentative of certain cohorts of melanomas (29), responded to 
Figure 4. MITF and primary resistance to MEK inhibition. A) DNA content 
fluorescence-activated cell sorting (FACS) analysis (assessing fractions of 
cells in G1, S, G2/M, or subG1 phase) of the indicated cell lines treated 
with 1µM PD184352 (PD) or dimethyl sulfoxide (DMSO) for 72 hours. 
Western blots of ERK phosphorylation (pERK) at concentrations of 0.2 
and 1 µM PD184352. ERK2 serves as loading control. B) Quantification of 
cells in the subG1 fraction of a FACS analysis of the indicated melanoma 
cell lines (R = resistant, S = sensitive) treated with 1µM PD184352 for 72 
hours. Bars represent means from three independent experiments; error 
bars refer to 95% confidence intervals. NS = P > .05; ***P < .001. Two-
sided analysis of variance (ANOVA) with Tukey’s post hoc test was used. 
C) Quantification of toluidine staining of live cells of the indicated mela-
noma cell lines treated with 3 µM PD184352 for 24 hours or DMSO only. 
DMSO-treated cells were set to 100%. Bars represent means from three 
independent experiments; error bars refer to 95% confidence intervals. 
NS = P > .05; ***P < .001. Two-sided ANOVA with Tukey’s post hoc test was 
used. A Western blot showing MITF expression and ERK2 as loading con-
trol is shown. D) Western blot of MITF, cleaved caspase 3, and phospho-
ERK (pERK) for 888mel and 501mel cells treated with a scrambled control 
or MITF-specific small interfering RNAs (siRNAs) (MI#1–#3) for 48 hours, 
followed by 24-hour exposure to 1 µM PD184352 (PD) or DMSO (D). ERK2 
was used as loading control. E) Quantification of cell survival. 501mel 
cells were treated with a scrambled control or MITF-specific siRNAs (MI#2 
and #3) for 48 hours, followed by 24-hour exposure to 0.5 µM PD184352 
(PD) or DMSO (D). They were then fixed and stained with toluidine blue, 
and the optical density at 555 nm was quantified. DMSO-treated cells 
were set to 100%, and treatment with 5 µM PD184352 was used as posi-
tive control. Bars represent means from three independent experiments; 
error bars refer to 95% confidence intervals; NS = P > .05; ***P < .001. 
Two-sided ANOVA with Tukey’s post hoc test was used.
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PD184352 with MEK inhibition even at low doses of inhibitor 
(0.2 µM), detectable by reduced ERK phosphorylation (Figure 4, 
A). However, whereas PD184352 induced a cytostatic effect in 
high-MITF-expressing cells, it produced cell death in low-MITF-
expressing cell lines (WM266-4, A375, SKMel-2), which was seen 
in an increased subG1 fraction and decreased cell numbers in 
SKMel-2, A375 and WM266-4 cells (Figure 4, A–C).
As seen with the acquired resistant cells, depletion of MITF 
from high-MITF- expressing primary resistant cell lines (888mel 
and 501mel cells) resulted in sensitization to PD184352, which led 
to the activation of an apoptotic program through caspase 3 cleav-
age (Figure 4, D) and reduced cell numbers at low concentrations 
of drug (Figure 4, E).
SMURF2 Depletion and MEK Inhibitor–Induced 
Cytotoxicity
When we analyzed primary MEK inhibitor–resistant melanoma 
cells for PAX3, we found increased expression in the resistant 
cell lines, which paralleled increased MITF expression (Figure 5, 
A). Furthermore, in line with PAX3 acting upstream of MITF, 
PAX3 depletion from A375 cells enhanced the proapoptotic 
effect of PD184352 detectable by increased caspase 3 cleavage 
(Supplementary Figure 1, B, available online). In addition, PAX3 
depletion further reduced the number of living cells in the presence 
of PD184352 (A375 control siRNA transfected, PD184352 treated 
vs A375 PAX3 siRNA transfected, PD184352 treated: 75.12% vs 
44.93%, difference = 30.19%, 95% CI = 27.50% to 41.80%, P < 
.001) (Figure  5, B). However, ectopic expression of MITF res-
cued A375 cells in which PAX3 was targeted by RNAi and MEK 
by PD184352 (A375 PAX3 siRNA transfected, PD184352 treated 
vs MITF-A375 PAX3 siRNA transfected and PD184352 treated: 
44.93% vs 85.07%, difference  =  40.15%, 95% CI  =  45.69% to 
34.60%, P < .001) (Figure 5, B). On the other hand, when MITF 
was depleted by RNAi in ectopic MITF-expressing A375 cells, they 
became responsive to PD184352, and the cell number was reduced 
(Figure 5, B).
TGF-β induced caspase 3 cleavage in response to the presence 
of PD184352 (Figure  5, C). Importantly, this caspase 3 cleavage 
in response to TGF-β was seen not only in MEK inhibitor–sensi-
tive WM266-4 cells but also in MEK inhibitor–resistant 501mel 
cells (Figure 5, C). The action of TGF-β and PD184352 was also 
reflected in effects on cell survival, most notably in MEK inhibi-
tor–resistant melanoma cells (Figure 5, D).
When we analyzed our panel of melanoma cells, we found sta-
tistically significantly (P = .001) increased SMURF2 expression in 
the primary MEK inhibitor–resistant cell lines compared with the 
MEK inhibitor–sensitive cell lines. (Figure 5, E). When SMURF2 
was depleted by RNAi in melanoma cell lines, this resulted in 
reduced PAX3 and MITF expression (Supplementary Figures 2 
and 3, available online), and because reduced PAX3 and MITF 
expression sensitizes melanoma cells to MEK inhibition (Figure 1, 
Figure 2, A, Figure 5, B), SMURF2 depletion strongly increased 
cell death in melanoma cells in the presence of PD184352 
(A375,scrambled control siRNA transfected, PD184352 treated 
vs A375, S2 siRNA transfected PD184352 treated: 79.58% vs 
13.47%, difference = 66.11%, 95% CI = 57.27% to 74.94%, P < 
.001) (Figure 5, F). However, ectopic expression of MITF, which 
is not affected by SMURF2 depletion (Supplementary Figure  1, 
C, available online), rescued the MEK inhibitor effect on the 
cell number (A375, S2 siRNA transfected PD184352 treated vs 
MITF-A375, S2 siRNA transfected PD184352 treated: 13.47% vs 
81.18%, difference = 67.71%, 95% CI = 73.95% to 61.47%, P < 
.001) (Figure 5, F). This suggests that reduced MITF expression 
is responsible for the cell death induced by SMURF2 depletion in 
PD184352-treated cells.
SMURF2 Expression in Melanoma and Effect of Its 
Depletion in Melanoma Cells
In our panel of melanoma cell lines, SMURF2 depletion had no 
major effect on cell viability (Figure  6, A). However, compared 
with single treatments, combined targeting of SMURF2 and MEK 
produced statistically significant (P < .001) cell death, most nota-
bly in the primary resistant cell lines (Figure 6, A). On the other 
hand, SMURF2 depletion had no noticeable effect on melanocytes 
(Figure  6, B). We also did not observe any major effect on cell 
survival when SMURF2 was depleted and MEK inhibited in non-
MITF-expressing but BRAF-mutant colon cancer cells (Figure 6, 
C), supporting a melanoma-specific role for SMURF2. When 
melanoma cells were grown as spheres in three-dimensional colla-
gen, SMURF2 depletion enhanced PD184352-induced cell death, 
visible by ethidium bromide uptake (Figure  6, D). Furthermore, 
targeting SMURF2 in fibroblasts did not stimulate tumor-promot-
ing effects otherwise produced by TGF-β (30), such as increased 
expression of VEGF and SPARC (Figure 6, E), which reveals an 
important difference between SMURF2 function and TGF-β 
stimulated signalling.
In advanced stage III and IV melanomas, SMURF2 RNA 
expression was statistically significantly increased compared with 
normal skin (mean of different skin samples and primary skin cells 
[normal melanocytes = 1] 1.05-fold vs stage III 15.40-fold, differ-
ence = 14.35, 95% CI = 21.91-fold to 6.80-fold, P < .001; normal 
1.05-fold vs stage IV 8.01-fold, difference = 6.96, 95% CI = 10.69-
fold to 3.25-fold, P < .001) (Figure 6, F). There was a correlation 
(r2 = 0.788) between SMURF2 and PAX3 expression (Figure 6, G), 
suggesting that the regulatory link between these two proteins is 
preserved in the tumors.
Effect of SMURF2 Depletion on MEK Inhibition In Vivo
In an approach that allows rapid assessment of cytotoxic effects 
in an in vivo setting, MEK inhibitor–resistant 501mel or MEK 
inhibitor–sensitive A375 cells were injected into zebrafish 
embryos (Figure 7, A; Supplementary Figure 4, available online). 
Both, pLKO-control and SMURF2-depleted cells (ie, cells sta-
bly expressing SMURF2-specific shRNAs; see also Figure  3, H) 
grew with no statistically significant difference (P > .05) in size over 
3 days (Figure 7, A; Supplementary Figure 4, B, available online). 
Xenografts formed by sensitive A375 cells showed no statistically 
significant tumor growth over a period of 3 days (day 1 to day 4) at 
20nM PD184352 (P > .05) (Supplementary Figure 4, B, available 
online). Resistant 501mel xenografts grew even in the presence 
of 100 nM drug (Figure 7, A), but additional SMURF2 depletion 
reduced the xenograft volume to less than 0.5-fold of the initial 
size measured at day 1 (DMSO: pLKO 3.26-fold vs shSMURF2 
2.78-fold size increase compared with day 1, difference  =  −0.48, 
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95% CI  =  −0.22 to 1.19, P > 0.05; PD184352: PLKO 1.90-fold 
vs shSMURF2 0.57-fold size increase compared with day 1, dif-
ference = −1.33, 95% CI = −0.64 to −2.05, P < .001) (Figure 7, A). 
A similar effect was observed for A375 xenografts (Supplementary 
Figure 4, B, available online).
SMURF2 depletion led to an approximately 100-fold enhanced 
sensitivity of melanoma cells to selumetinib, a MEK inhibitor 
that produces limited responses in melanoma patients (3) (A375: 
(GI50) = 2.2 µM, 95% CI = 2.114 to 2.286; pLKO: (GI50) = 1.69 µM, 
95% CI  =  1.60 to 1.81  µM; S2C4: (GI50)  =  26.62 nM, 95% 
CI = 20.42 to 36.73 nM; S2C14 (GI50): 23.3 nM, 95% CI = 17.24 
to 31.60) (Figure  7, B). In mice, selumetinib reduces xenograft 
growth at doses of 25 to 30 mg/kg twice daily (9,31). However 
pharmacokinetic analyses revealed that a dose of 10 mg/kg once 
per day produces drug exposures in mice similar to those achieved 
in clinical use (32). Therefore, we used doses of 3 and 10 mg/
kg once daily, which did not have a statistically significant effect 
(P > .05) on the growth of parental A375-pLKO tumors (Figure 7, 
Figure 5. SMURF2 confers resistance to MEK inhibition in melanoma 
cells. A) Western blot of the indicated cell lines for MITF, PAX3, and 
ERK2 (loading control). R = resistant, S = sensitive. B) Quantification of 
cell survival. A375 and MITF-A375 cells (stably expressing MITF from 
an ectopic promoter) were treated with a scrambled control, PAX3- 
(PAX3#1) or MITF (MI#1)-specific small interfering RNAs (siRNAs), 
for 48 hours, followed by 24-hour treatment with 1 µM PD184352 or 
dimethyl sulfoxide (DMSO). They were then stained with toluidine 
blue, and the optical density at 555 nm was quantified. DMSO-treated 
cells were set to 100%. Bars represent means from three independ-
ent experiments; error bars refer to 95% confidence intervals; ***P < 
.001. Two-sided analysis of variance (ANOVA) with Tukey’s post hoc test 
was used. C) Western blot of WM266-4 and 501mel cells for cleaved 
caspase 3, pERK, and ERK2 (loading control). The cells were either 
unstimulated (–) or stimulated (transforming growth factor β [TGF–
β]) for 24 hours with 5 ng/ml TGF-β in the presence of DMSO (D) or 
1 µM PD184352 (PD). D) Quantification of cell survival. The indicated 
cell lines were treated with TGF-β for 48 hours, followed by 24-hour 
exposure to 1 µM PD184352 (PD) or DMSO (D). They were then stained 
with toluidine blue, and the optical density at 555 nm was quantified. 
DMSO-treated cells were set to 100%. Bars represent means from 
three independent experiments; error bars refer to 95% confidence 
intervals; ***P < .001. Two-sided ANOVA with Tukey’s post hoc test was 
used. E) Quantitative real-time polymerase chain reaction and Western 
blot analysis of SMURF2 expression in melanoma cell lines. The 
expression of SMURF2 is shown as fold expression compared with 
normal human melanocytes (NHM), in which SMURF2 expression was 
set to 1. Bars represent means from three independent experiments; 
error bars refer to 95% confidence intervals; ***P < .001. Two-sided 
ANOVA with Dunnett’s post hoc test was used. F) Quantification of 
cell survival. A375 and MITF-A375 cells were treated with a scrambled 
control (SC) or SMURF2 pooled siRNAs (S2-p) for 48 hours, followed 
by 24-hour exposure to 1 µM PD184352 or DMSO, and quantified using 
toluidine blue. DMSO-treated cells were set to 100%. Bars represent 
means from three independent experiments; error bars refer to 95% 
confidence intervals; NS = P > .05; ***P < .001. A two-sided Student’s 
t test was used.
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Figure 6. SMURF2 overexpression and specificity in targeting SMURF2 in 
melanoma cells. A) Quantification of cell survival. The indicated cell lines 
were treated with scrambled control or SMURF2-specific small interfering 
RNAs (siRNAs) (siSMURF2#1) for 48 hours, followed by 24-hour exposure 
to dimethyl sulfoxide (DMSO) or 1 µM PD184352. They were then they 
were stained with toluidine blue, and the optical density at 555 nm was 
quantified. DMSO-treated cells were set to 100%. Bars represent means 
from three independent experiments; error bars refer to 95% confidence 
intervals; ***P < .001. Two-sided analysis of variance (ANOVA) with Tukey’s 
post hoc test was used. B) Quantification of cell survival. Normal melano-
cytes (NHM) were treated with a scrambled control or a SMURF2 pool 
of 4 (S2-p) siRNAs for 48 hours, followed by 24-hour exposure to 1 µM 
PD184352 (PD) or DMSO (D). They were then then fixed and stained with 
toluidine blue and quantified. DMSO-treated cells were set to 100%. Bars 
represent means from three independent experiments; error bars refer 
to 95% confidence intervals; NS = P > .05. A  two-sided Student’s t test 
was used. C) Quantification of cell survival. The colon cancer cell lines 
RKO and HT29 were treated with a scrambled control or two SMURF2-
specific siRNAs (#1 and #2) for 48 hours, followed by 24-hour exposure to 
1 µM PD184352 or DMSO. They were then fixed and stained with toluidine 
blue and quantified. DMSO-treated cells were set to 100%. Bars repre-
sent means from three independent experiments; error bars refer to 95% 
confidence intervals; NS = P > .05; ***P <  .001. A two-sided Student’s t 
test was used. D) Spheres of green fluorescent protein–expressing A375 
cells, A375-pLKO-expressing A375 cells, or small hairpin SMURF 2(shS-
MURF2)–expressing A375 cells (clone S2–C14) in three-dimensional col-
lagen were treated with DMSO or PD184352 for 3 days. Nonfixed spheres 
were stained with ethidium bromide (EtBr), and images were taken. Scale 
bar = 200 µm. E) Quantitative real-time polymerase chain reaction (PCR) 
analysis of VEGF and SPARC expression in primary fibroblasts either 
untreated (–) or treated (transforming growth factor [TGF-β]) with 5 ng/ml 
TGF-β or transfected with either a scrambled control or individual SMURF2-
specific siRNAs (S2#1 and #2). Bars represent means from five independ-
ent experiments; error bars refer to 95% confidence intervals; NS = P > .05; 
***P < .001. A two-sided Dunnett’s t test was used. F) Quantitative real-
time PCR analysis of SMURF2 expression in normal skin cells and stage III 
(n = 36) and stage IV (n = 41) melanomas. The expression was normalized 
to β-actin. Box plots with mean values for SMURF2 expression are shown. 
Normal = normal skin (n = 6), supplemented with additional cDNA derived 
from human fibroblasts, keratinocytes, and melanocytes. The expression 
in melanocytes was set to 1. ***P < .001. A two-sided Student’s t test to 
compare expression in stage III and stage IV melanomas with normal was 
used. G) Linear regression analysis of relative SMURF2 and PAX3 expres-
sion levels in stage III melanomas. Goodness of Fit: r2 + 0.7883. A ranking 
linear regression fit with Wald–Wolfowitz runs test was used to compare 
SMURF2 and PAX3 expression from cDNA array data.
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Figure 7. SMURF2 depletion sensitizes melanoma cells to MEK inhibition 
in vivo. A) RFP-expressing 501mel pLKO or small hairpin SMURF2 (shS-
MURF2) cells were injected into zebrafish larvae that were 48 hours post-
fertilization, and the larvae were treated with either 100 nM PD184352 
or the vehicle dimethyl sulfoxide (DMSO). Three days after drug addi-
tion, the xenografts were imaged. Scale bar = 36 µm. Quantification of 
xenograft volumes (n = 19) was performed before drug addition on day 
1 and on day 4 using Volocity software. Fold xenograft size indicates the 
change in volume between day 1 and day 4.  Black squares represent 
individual fish injected with pLKO-501mel cells; black triangles repre-
sent individual fish injected with 501mel-shSMURF2 cells. The horizontal 
bar indicates the mean value of the fold xenograft size in the respective 
group of zebrafish. A two-sided Student’s t test was used to calculate P 
values; NS = P > .05; ***P < .001. B) Dose–response curve of cell sur-
vival in the presence of selumetinib. The indicated cell lines were treated 
with the indicated concentrations of selumetinib for 24 hours before they 
were fixed, stained with toluidine blue, and quantified. DMSO-treated 
cells were set to 100%, and drug dose–response curves were analyzed 
with a nonlinear regression curve fit model. C) Nude mice bearing 
tumors from A375-pLKO cells (empty vector) were treated with either 
vehicle (DMSO) or selumetininb (3 or 10 mg/kg once daily) for 29 consec-
utive days. The results show mean volumes measured on days 7, 12, 19, 
26, and 29 for groups of five mice with error bars to represent the 95% 
confidence intervals. A two-sided Student’s t test was used to calculate 
P values for day 29. D) Nude mice bearing tumors from SMURF2-depleted 
A375-S2-C14 cells were treated with either vehicle (DMSO) or selu-
metininb (3 or 10 mg/kg once daily) for 29 consecutive days. The results 
show mean volumes measured on days 7, 12, 19, 26, and 29 for groups 
of five mice with error bars to represent the 95% confidence intervals. 
A two-sided Student’s t test was used to calculate P values for day 29. 
E) Quantification of tumor volume at day 29. Results shown represent a 
single experiment in which five mice per group were treated. Bars rep-
resent means from each group of mice; error bars refer to 95% confi-
dence intervals; **P = .003; *P = .03; NS = P > .05. A two-sided Student’s 
t test was used. The horizontal line at 100 mm3 indicates the mean tumor 
volume at the beginning of drug treatment. F) Model of survival and 
growth regulation in melanoma cells. The cooperation of MEK and MITF 
is required for efficient survival. MEK predominantly regulates cell cycle 
progression through ERK but also activates survival signals. MITF con-
tributes to the regulation of cell cycle progression and is required to 
suppress apoptosis. SMURF2 depletion on its own reduced cell cycle 
progression, which is entirely in line with decreased MITF expression 
(37). Under these conditions, MITF levels appear to be sufficient to pro-
vide survival signals as long as MEK is fully active.
Downloaded from https://academic.oup.com/jnci/article-abstract/105/1/33/877707
by Library Institute of Cancer Research user
on 06 August 2018
Vol. 105, Issue 1  |  January 2, 201244 Articles | JNCI
C and E). However, growth of tumors derived from SMURF2-
depleted A375 cells was greatly reduced at both dosing regimens, 
with 10 mg/kg selumetinib almost completely suppressing tumor 
growth and 3 mg/kg resulting in approximately 77% reduction in 
tumor size compared with tumors in control mice treated with the 
vehicle DMSO (shSMURF2/3mg/kg: difference = 77.15%, 95% 
CI = 10.62% to 143.72%, P = .03; shSMURF2/10mg/kg: differ-
ence = 97.9%, 95% CI = 38.65% to 155.50%, P = .005) (Figure 7, 
D and E).
Discussion
The efficacy of most anticancer drugs is closely linked to their 
cytotoxic potential. Cytostatic drugs can only stop tumor growth, 
which increases the risk for the development of acquired resist-
ance because it allows for the survival and selection of cells that 
are able to continue to proliferate in the presence of the drug. 
Therefore, enhancing the cytotoxic potential of a drug will not 
only improve the tumor response, but it will also reduce the emer-
gence of acquired resistance. We found that increased expression of 
MITF, PAX3, and SMURF2 allows melanoma cells to escape the 
proapoptotic effects of MEK inhibition. We identified SMURF2 as 
a regulator of PAX3 expression and, consequently, MITF expres-
sion and demonstrate that exploiting this mechanism dramatically 
enhances the cytotoxic potential of the MEK inhibitors PD184352 
(CI-1040) and selumetinib (AZD6244) in vitro and in vivo.
In principle, MEK inhibitors can exert cytotoxic effects by 
directly activating the apoptotic programme (6–8,33). However, 
for this to occur, high drug concentrations and long-term drug 
exposure are required, suggesting that MEK’s contribution to the 
regulation of apoptosis is not major. Rather, it appears that the pre-
dominant function of MEK is to regulate cell cycle progression 
through ERK, which is in agreement with observations that loss 
of ERK phosphorylation leads to a G1 arrest, but not always to 
the induction of apoptosis (7,10). In line with these findings, we 
identified cells that responded to the MEK inhibitor PD184352 
with target inhibition and reduced proliferation but were still able 
to propagate in the long term, a situation likely to be found in a 
tumor. We found that these cells are resistant to the proapoptotic 
effects of MEK inhibition and that, although ERK activity is very 
low, it is still sufficient to promote cell cycle progression. This find-
ing is of great relevance because it highlights the challenge of tar-
geting the MAP-kinase pathway as a single-agent treatment. It is, 
therefore, of great importance to identify factors that will predict 
and moreover enhance the sensitivity to MEK inhibitors.
We identified the melanocyte-specific transcription factor 
MITF as a predictive marker for the sensitivity of melanoma cells 
toward the cytotoxic effect of MEK inhibitors. We found that high 
MITF expression protects cells from MEK inhibitor–induced cell 
death, which is striking considering that MITF is amplified in up to 
20% of melanomas (34). MITF is a central regulator of melanoma 
cell fate because it controls differentiation, proliferation, and inva-
sion (21,22,24). Although we do not know the exact mechanism as 
to how MITF regulates survival in cells in which MEK is inhibited, 
MITF is a known regulator of melanoma cell survival, where it can 
induce the expression of BCL-2 or ML-inhibitor of apoptosis and 
protect cells from cytotoxic agents (34–36).
We have shown previously that MITF contributes to cell cycle 
progression downstream of BRAF (37), but now we show that it 
also cooperates with MEK to provide survival signals (Figure 7, F). 
Although MEK can activate survival signals through ERK (7,8), 
it is the cooperation of both MEK and MITF that is required for 
survival. In this context, we identified SMURF2 as a regulator of 
MITF expression through PAX3 (Figure 7, F). SMURF2 depletion 
alone reduced cell cycle progression (Supplementary Figure 2, B, 
available online), which is entirely in line with decreased MITF 
expression. However MITF levels appear to be still sufficient to 
provide survival signals as long as MEK is fully active because 
we observed no effects on cell viability with SMURF2 depletion 
alone. Thus, SMURF2 itself seems to be only relevant for mela-
noma cells when MEK is inhibited. Importantly, we also found 
that depleting SMURF2 from melanocytes did not have any 
effect on their growth and survival. This suggests that targeting 
SMURF2 in normal cells does not affect viability or growth prob-
ably because of compensatory mechanisms, an assumption that 
is further supported by the fact that SMURF2-/- mice are viable 
and develop healthy and normal to adulthood (28). These mice 
eventually develop tumors; however, this occurs with a very long 
latency at an age of more than 20  months (38,39), suggesting 
that loss of SMURF2 function does not produce any immediate 
adverse effects.
SMURF2 is a HECT-domain E3 ubiquitin ligase, which reg-
ulates the turnover of inhibitory SMADs and associated TGF-β 
receptors as well as regulatory SMADs (27). SMURF2 also regu-
lates cell polarity, motility, and senescence in a SMAD- independ-
ent manner (40–43). These findings suggest that SMURF2 plays an 
important role in various aspects relevant for tumor initiation and 
progression in a SMAD-dependent as well as SMAD-independent 
manner. We found that SMURF2 regulates SMAD2 levels in mela-
noma cells (Figure 3, E; Supplementary Figure 2, available online). 
However, although SMAD2 has been shown to regulate the sup-
pression of PAX3 in melanocytes (26), the complete mechanism as 
to how SMURF2 suppresses PAX3 is not clear and might involve 
additional factors other than SMAD2. We and others detected high 
expression levels of SMURF2 in tumors compared with normal 
tissue (42,44), suggesting a deregulation of this ubiquitin ligase in 
cancer. On the other hand, the neutralization of SMURF2 activity 
by the ubiquitin-specific peptidase USP15 is important for TGF-
β-mediated glioblastoma progression (45), suggesting tumor-spe-
cific differences in SMURF2 function. A tumor-specific function 
is supported by our finding that SMURF2 depletion from colon 
cancer cells did not prime these cells for MEK inhibitor cytotoxic-
ity despite a mutant BRAF status.
We have identified SMURF2 as a potential therapeutic target in 
melanoma. However, there are clear limitations to our study. First 
we used xenograft assays to assess combined therapy in vivo, and 
this approach does not consider the heterogeneity found in a real 
tumor situation. Second, no SMURF2 inhibitor is available, and we 
had to rely on knock-down experiments in our study, which might 
produce different effects than inhibition of SMURF2 activity. 
Finally, we have no clinical data showing that increased expression 
of SMURF2 or MITF correlates with MEK inhibitor resistance, 
but we hope to be able to collect such samples in the future and 
analyze them for these potential resistance regulators.
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Recent experiences with targeting kinases in patients have 
exposed the inevitable risk of developing resistance because of com-
plex kinase networks and feedback mechanisms (10,13–16,46,47). 
Therefore, targeting a nonkinase might provide an advantage. E3 
ubiquitin ligases gained a lot of attention as potential drug targets 
when the MDM2/p53 inhibitors Nutlin1–3 were discovered, but 
initial efforts to identify other E3 ubiquitin ligase inhibitors proved 
difficult (48). On the other hand, recent successes with inhibitors 
of apoptosis are encouraging (48), suggesting that developing a 
SMURF2-specific inhibitor might be possible. Alternatively, fur-
ther characterization of the SMURF2, PAX3, and MITF regula-
tion in melanoma may lead to the identification of better druggable 
proteins that can be targeted in MEK inhibitor combination thera-
pies. Our results strongly suggest that in melanoma such therapies 
might have the potential to increase the frequency of complete 
responses and reduce the risk of the development of acquired 
resistance.
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